BE502262A - - Google Patents
Info
- Publication number
- BE502262A BE502262A BE502262DA BE502262A BE 502262 A BE502262 A BE 502262A BE 502262D A BE502262D A BE 502262DA BE 502262 A BE502262 A BE 502262A
- Authority
- BE
- Belgium
- Prior art keywords
- antibiotic
- terramycin
- streptomycin
- mixture
- composition
- Prior art date
Links
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 64
- 230000003115 biocidal Effects 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 56
- 229960000625 Oxytetracycline Drugs 0.000 claims description 36
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 36
- 229940063650 Terramycin Drugs 0.000 claims description 36
- 244000005700 microbiome Species 0.000 claims description 30
- 229960005322 Streptomycin Drugs 0.000 claims description 27
- 239000003242 anti bacterial agent Substances 0.000 claims description 26
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims description 17
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims description 17
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims description 17
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims description 17
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims description 17
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims description 17
- 229940079866 intestinal antibiotics Drugs 0.000 claims description 17
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 238000010790 dilution Methods 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000005755 formation reaction Methods 0.000 claims description 6
- 230000001747 exhibiting Effects 0.000 claims description 3
- 230000000813 microbial Effects 0.000 claims description 3
- 230000002980 postoperative Effects 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 201000009910 diseases by infectious agent Diseases 0.000 description 12
- 230000002458 infectious Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 229960002385 Streptomycin Sulfate Drugs 0.000 description 7
- 241000588769 Proteus <enterobacteria> Species 0.000 description 5
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 200000000019 wound Diseases 0.000 description 3
- 230000036740 Metabolism Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000845 anti-microbial Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XGAKTAXPHNYSTK-RMIBZTJPSA-N 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;hydrochloride Chemical compound Cl.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O XGAKTAXPHNYSTK-RMIBZTJPSA-N 0.000 description 1
- CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229960001162 Dihydrostreptomycin Sulfate Drugs 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 241000187419 Streptomyces rimosus Species 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000003385 bacteriostatic Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960002222 dihydrostreptomycin Drugs 0.000 description 1
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE502262A true BE502262A (zh) |
Family
ID=143821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE502262D BE502262A (zh) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE502262A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2805975A (en) * | 1952-12-31 | 1957-09-10 | Pfizer & Co C | Antibiotic embalming process |
-
0
- BE BE502262D patent/BE502262A/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2805975A (en) * | 1952-12-31 | 1957-09-10 | Pfizer & Co C | Antibiotic embalming process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2676080B2 (ja) | 非抗バクテリア性テトラサイクリン組成物 | |
| DE69930944T2 (de) | Bacillus coagulans-zusammensetzung und deren verwendung | |
| US4229430A (en) | Oral composition for improving oral health | |
| JPH09501702A (ja) | 増強された抗生物質組成物 | |
| Greenstein | Povidone‐iodine's effects and role in the management of periodontal diseases: a review | |
| WO2013112876A1 (en) | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof | |
| EP0871438B1 (en) | Use of alpha-hydroxy acids in the manufacture of a medicament for the treatment of inflammation | |
| US20220117924A1 (en) | Compositions of Glycerol and /or Non-Toxic Amino Acids for Inhibiting and Destroying Biofilm, including Related Methods | |
| US6248718B1 (en) | Lesion-directed dry dosage forms of antibacterial agents for the treatment of acute mucosal infections of the oral cavity | |
| EP2165704B1 (fr) | Utilisation de l'alvérine dans le traitement des affections cutanées | |
| JP6249438B2 (ja) | 口腔衛生改善活性組成物 | |
| JP6600124B2 (ja) | 菓子 | |
| WO2016041958A1 (fr) | Antimicrobiens potentialises | |
| BE502262A (zh) | ||
| EP0310476A1 (fr) | Composition inhibitrice ou destructrice d'au moins un être vivant unicellulaire renfermant du fluor F- et du lithium Li+ | |
| EP1902721A1 (fr) | Compositions médicales et nutritionnelles à base de vaccinium macrocarpon | |
| CA2384192C (en) | Pharmaceutical composition, comprising eucalyptus oil and orange oil | |
| CN109985063A (zh) | 一种高效抑菌药物组合物及其制备方法与应用 | |
| BE469075A (zh) | ||
| BE505709A (zh) | ||
| Condon et al. | Aztreonam concentration in abdominal tissues and bile | |
| US20180161294A1 (en) | Broad spectrum pharmacological composition for treatmentof various infections and diseases and methodsof use | |
| Andersen et al. | Pivmecillinam in the treatment of therapy resistant urinary tract infections: A comparison with pivmecillinam, pivampicillin and their combination | |
| CA1221635A (fr) | Composition a activite pharmaceutique amelioree et utilisation de celle-ci pour des usages veterinaires | |
| KR100474534B1 (ko) | 치아 질환의 예방 및 치료용 조성물 |